Clinical Trial: A Study to Evaluate the Efficacy and Safety of Concomitant Use of Eplontersen and ALXN2220 Compared With Eplontersen and Placebo for Adults Participants With ATTR-CM.

U.S., May 28 -- ClinicalTrials.gov registry received information related to the study (NCT07608354) titled 'A Study to Evaluate the Efficacy and Safety of Concomitant Use of Eplontersen and ALXN2220 Compared With Eplontersen and Placebo for Adults Participants With ATTR-CM.' on May 12.

Brief Summary: The purpose of this randomised, double-blind, placebo-controlled, multicenter study is to evaluate the efficacy and safety of concomitant use of eplontersen and ALXN2220 compared with eplontersen and placebo in adult participants with Transthyretin-mediated amyloid cardiomyopathy (ATTR-CM).

Study Start Date: June 30

Study Type: INTERVENTIONAL

Condition: Transthyretin Amyloid Cardiomyopathy (ATTR-CM)

Intervention: DRUG: Eplontersen

Eplon...